VRCA Corporate presentation

Page 1

Page 2

Not For Promotional Use Copyright © 2026 Verrica Pharmaceuticals. All rights reserved. Not For Promotional Use 2 Disclaimer Certain information contained in this presentation and statements made orally during this presentation relates to or is based on studies, publications, surveys and other data obtained from third-party sources and Verrica’s own internal estimates and research. While Verrica believes these third-party sources to be reliable as of the date of this presentation, it has not independently verified, and makes no representation as to the adequacy, fairness, accuracy or completeness of, any information obtained from third-party sources. While Verrica believes its internal research is reliable, such research has not been verified by any independent source. This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act, that involve substantial risks and uncertainties. In some cases, you can identify forward-looking statements by the words “may, ” “might, ” “will, ” “could, ” “would, ” “should, ” “expect, ” “intend, ” “plan, ” “objective, ” “anticipate, ” “believe, ” “estimate, ” “predict, ” “project, ” “potential, ” “continue” and “ongoing, ” or the negative of these terms, or other comparable terminology intended to identify statements about the future. These statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward- looking statements. Although we believe that we have a reasonable basis for each forward-looking statement contained in this presentation, we caution you that these statements are based on a combination of facts and factors currently known by us and our expectations of the future, about which we cannot be certain. Forward-looking statements include statements about: our expectations regarding the commercialization of YCANTH (VP-102) for the treatment of molluscum contagiosum as well as our plans to develop and commercialize our product candidates; the timing of our planned clinical trials for our product candidates; our ability to maintain regulatory approvals for YCANTH (VP- 102) for the treatment of molluscum contagiosum or obtain approval for additional indications for YCANTH (VP-102); the clinical utility of our product candidates; our commercialization, marketing and manufacturing capabilities and strategy; our expectations about the willingness of healthcare professionals to use YCANTH (VP-102) for the treatment of molluscum contagiosum, VP-315 for basal cell carcinoma and any of our product candidates; our expectations about third-party payors to reimburse or patients to pay for YCANTH (VP-102) for the treatment of molluscum contagiosum and any of our product candidates; our intellectual property position; our competitive position and the development of and projections relating to our competitors or our industry; our expectations regarding the market size of the indications we’re pursuing; and our estimates regarding future revenue, expenses and needs for additional financing. You should refer to the "Risk Factors" in our Annual Report on Form 10-K, our most recent Quarterly Report on Form 10-Q, and our other filings made with the SEC for a discussion of important factors that may cause our actual results to differ materially from those expressed or implied by our forward- looking statements. As a result of these factors, we cannot assure you that the forward-looking statements in this presentation will prove to be accurate. Furthermore, if our forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame, or at all. The forward-looking statements in this presentation represent our views as of the date of this presentation. We anticipate that subsequent events and developments may cause our views to change. We undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this presentation. Unless otherwise indicated or the context otherwise requires, all references in this presentation to "the Company, " "we, " "our, " "ours, " "us" or similar terms refer to Verrica Pharmaceuticals Inc. "Verrica," the Verrica logo, YCANTH (VP-102) and other trademarks or service marks of Verrica Pharmaceuticals Inc. appearing in this presentation are the property of Verrica Pharmaceuticals Inc. This presentation contains additional trade names, trademarks and service marks of others, which are the property of their respective owners.

Page 3

Not For Promotional Use Copyright © 2026 Verrica Pharmaceuticals. All rights reserved. Not For Promotional Use 3 Verrica Snapshot YCANTH®: Commercially Available Product In the United States And Japan For The Treatment Of Molluscum Contagiosum Label Expansion Opportunity For YCANTH® With Ongoing Global Phase 3 Program For The Treatment of Common Warts VP-315: Phase 3 Ready For Basal Cell Carcinoma (BCC) Supported By Phase 2 Primary And Potential Abscopal Data And Favorable Regulatory Feedback Multiple Key Inflection Points Expected In Early To Mid 2027, Including Topline Data In Common Warts for COVE-2 (Q1 2027) And COVE-3 (Mid-2027) Phase 3 Trials

Page 4

Not For Promotional Use Copyright © 2026 Verrica Pharmaceuticals. All rights reserved. COMMON WARTS: THE OPPORTUNITY • ~22 million U.S. patients with no FDA-approved product — more than 3x the molluscum addressable population1 • Potential $1 billion+2 market opportunity, the largest unmet need in dermatology • Global Phase 3 program substantially funded by Torii Pharmaceutical providing the first $40M (~90%) of cash for trial costs, with Verrica’s portion to be repaid out of future royalties and milestones (total program costs shared 50/50) • Verrica retains global commercial rights outside of Japan and Israel, with topline Phase 3 data expected in Q1 and mid-2027 YCANTH: One Platform, Two Indications MOLLUSCUM CONTAGIOSUM: THE FOUNDATION • First FDA-approved and only HCP-administered treatment for molluscum contagiosum, supported by 3 successful Phase 3 studies and over 120,000 applicators dispensed to date • In 2025, reported product revenue of $15.3 million, up +130% YOY , while reducing SG&A expense by ~40%; reported H1’26 product revenue of ~$9.4M, an increase of ~18% YOY • YCANTH approved in Japan in September 2025 and launched by partner Torii Pharmaceutical in February 2026 • Alignment gained with European Medicines Agency on regulatory path with no additional clinical trials 4 LEVERAGING OUR FOUNDATION TO EXPAND THE MARKET FOR YCANTH • Same active ingredient and drug-device combination (cantharidin 0.7%, VP-102) — same GMP manufacturing and 2-year shelf-stable supply chain • Informed Phase 3 design: dosing regimen mirrors Cohort 2 of Phase 2 COVE-1, which showed >50% complete clearance after 4 treatments • Established commercial infrastructure from molluscum can be leveraged for common warts, as many of the same dermatologists and pediatricians who can treat molluscum patients also see patients with common warts • Interim analysis for first Phase 3 trial supported completion of study with no additional patients recommended to be included 1) IMS National Disease and Therapeutic Index (NDTI) Rolling 5 Years Ending June 2016. Nguyen et al, Laser Treatment of Nongenital Verrucae A Systemic Review. JAMA Dermatology. 2016; 152(9): 1025-1033; Prevalence in the U.S. of 5.1% to 11.5% in children aged 0-16 years. (Fam Pract. 2014 Apr;31(2):130-6). U.S. Census estimates ~69.4MM children aged 0 to 16 years in 2016 2) Based on best case scenario management projections reflect base case scenario.

Page 5

Not For Promotional Use Copyright © 2026 Verrica Pharmaceuticals. All rights reserved. Not For Promotional Use VP-315: Basal Cell Carcinoma Program VP-315 represents one of the most compelling late-stage dermatologic-oncology opportunities in development today • Phase 3-ready asset with aligned path to registration as an innovative, non-surgical innovative treatment for non-malignant skin cancer • 97% overall objective response rate in Phase 2 Study • Favorable safety and tolerability profile (no treatment-related SAEs in Phase 2 Study) • FDA alignment from EOP2 meeting for streamlined clinical development program (two Phase 3 placebo-controlled trials, 100 patients each with primary endpoint on week 12 and long-term follow-up as a post-approval requirement), which potentially accelerates time and lowers cost to regulatory approval • High prevalence of 3.6 million annual US cases per year1 with limited non-surgical treatment options representing large unmet need in growing market with a total addressable market of $5.5 billion2 • Potential to expand target population to include Squamous Cell Carcinoma (SCC), further increasing the total addressable market by 1.8 million annual cases per year3 • Strong patient interest: Many patients would favor VP-315 over existing therapeutic options 5 $5.5 Billion Total Addressable Market in US for Basal Cell Carcinoma2 3.6 Million Annual US cases diagnosed1 1) https://www.skincancer.org/skin-cancer-information/basal-cell-carcinoma/ 2) https://www.biospace.com/press-releases/basal-cell-carcinoma-market-size-to-reach-usd-9-70-billion-by-2035-impelled-by-increased-awareness-and-early-diagnosis 3) https://www.skincancer.org/skin-cancer-information/squamous-cell-carcinoma/

Page 6

Not For Promotional Use Copyright © 2026 Verrica Pharmaceuticals. All rights reserved. Not For Promotional Use Program / Asset Indication Pre-IND Phase 2 Phase 3 Approval YCANTH (VP-102) Molluscum Contagiosum Active Product Development Candidates VP-102 Common Warts VP-315 Basal Cell Carcinoma 6 1) Excluding any additional Patent Term Adjustment (PTA) or Patent Term Extension (PTE). 2) Verrica’s portion to be repaid out of future royalties and milestones; total program costs shared 50/50 with Torii. Verrica Pipeline • U.S. IP protection expected to expire between 2036 and 20411 • Global IP protection allows for licensing opportunities outside Japan and Israel • Preparation for submission in EU underway YCANTH • Leverages YCANTH’s existing platform and infrastructure; Torii provides the first $40M (~90%) of Phase 3 trial costs 2 • No current FDA approved product • Data from first Phase 3 trial expected in Q1 2027 and second Phase 3 trial expected in mid-2027 VP–102: Common Warts • Compelling Phase 2 program with strong efficacy and safety profile • U.S. IP protection expected to expire between 2032 and 2045 1 • Expansion opportunities into other skin cancers, including SCC VP-315 Phase 3 Ready, planning activities underway COVE-2 100% enrolled; COVE-3 > 50% enrolled Commercialized in the US and Japan

Page 7

Not For Promotional Use Copyright © 2026 Verrica Pharmaceuticals. All rights reserved. Not For Promotional Use Entrepreneurial Management Team with Extensive Experience 77 Selected Development and Commercialization Product Experience from the Leadership and Commercial Team APADENOSONNAFTINTOPROL XL SYNALAR CLINDACIN Jayson Rieger, PhD, MBA President & Chief Executive Officer John Kirby Interim Chief Financial Officer Noah Rosenberg, MD Chief Medical Officer David Zawitz, CFA Chief Operating Officer Chris Chapman Chief Commercial Officer

Page 8

Page 9

Not For Promotional Use Copyright © 2026 Verrica Pharmaceuticals. All rights reserved. Not For Promotional Use Overview Caused by a pox virus Primarily infects children, with the highest incidence occurring in children <14 years old Highly contagious with risk for secondary infection including cellulitis If untreated, lesions persist an average of 13 months, although in some patients clearance can take up to five years(1) Often leads to anxiety and social challenges for the patients and parents and negatively impacts quality of life 1) www.aad.org/publwww.aad.org/public/diseases/a-z/molluscum-contagiosum-symptoms Molluscum Background Etiology and Clinical Presentation TRANSMISSION • Skin to skin contact • Sharing of contaminated objects (e.g., clothing, towels, swimming pool toys) DIAGNOSIS & SYMPTOMS • Typically 10 to 30 lesions • 100+ lesions can be observed • Lesions may be the only sign of infection • Can be diagnosed with skin biopsy but often diagnosed visually • May be asymptomatic but can often be painful and itchy COMPLICATIONS • Skin irritation, inflammation, and re-infection • Follicular or papillary conjunctivitis if lesions on eyelids • Cellulitis 9

Page 10

Not For Promotional Use Copyright © 2026 Verrica Pharmaceuticals. All rights reserved. Not For Promotional Use YCANTH® is the Only HCP Administered FDA Approved Treatment for Molluscum Supported by robust Phase 3 data and designed for consistent and targeted administration Topical solution in a single-use applicator Active ingredient cantharidin (0.7%) in a proprietary topical formulation Single-use applicator to reduce cross-contamination and facilitate application of the topical solution Small opening allows for targeting of affected skin GMP-controlled, shelf-stable for 2 years, consistent topical formulation Allows for reliable dosing/administration Oral deterrent to help mitigate the risk of accidental ingestion Visualization agent to identify treated lesions 10 Safety Adverse reactions were (expected) primarily local skin reactions at the application site Majority of AEs were mild to moderate in severity No serious adverse reactions were reported

Page 11

Not For Promotional Use Copyright © 2026 Verrica Pharmaceuticals. All rights reserved. Phase 3 Studies Demonstrated Significant Benefit to Patients Regardless of Disease Duration * ITT (Intent-to-treat) population included all patients randomized to receive either VP-102 or vehicle. Percentage of Subjects Achieving Complete Clearance at Day 84 By Disease Duration (Post-hoc, Pooled, ITT population*) 0 20 40 60 80% Subjects Disease Duration (months) Vehicle VP-102 ≤ 12 months > 12 months 16.7% (n=198) 48.9% (n=276) 5.0% (n=20) 58.8% (n=34) p < 0.0001 p < 0.0001 Median Percent Change from Baseline Count at Day 84 By Disease Duration (Post-hoc, Pooled, ITT population*) -100 -50 0 % CHange in Lesion CountDisease Duration (months) Vehicle VP-102 ≤ 12 months > 12 months p < 0.0001 p < 0.0001 -47.9% -100% -100% -50.9% 11

Page 12

Page 13

Not For Promotional Use Copyright © 2026 Verrica Pharmaceuticals. All rights reserved. Not For Promotional Use 13 1) IMS National Disease and Therapeutic Index (NDTI) Rolling 5 Years Ending June 2016. Nguyen et al, Laser Treatment of Nongenital Verrucae A Systemic Review. JAMA Dermatology. 2016; 152(9): 1025-1033 2) IQVIA Anonymous Longitudinal Patient Level Data (APLD) for 12 months ending September 2018 Verruca Vulgaris (Common Warts) Overview • No Currently FDA-approved drug for the treatment of common warts • U.S prevalence of 22 million(1), with 1.5 million(2) diagnosed annually Etiology and Clinical Presentation TRANSMISSION • Skin to skin contact • Touching of contaminated objects DIAGNOSIS & SYMPTOMS • Dome shaped flesh-colored lesions commonly on the hands, fingers, knees or elbows • Lesions may occur in groups or in a linear pattern • Lesions can cause considerable pain and discomfort, may spread with skin trauma, and can be itchy COMPLICATIONS • Scarring may occur • Dyspigmentation of affected areas • Bacterial superinfection of lesions • Irritation, pain, and redness of surrounding skin • Caused by human papilloma virus (HPV) • Infects patients of all ages • Persistent infection, highly refractory • Typically 2-5 lesions CONFIDENTIAL

Page 14

Not For Promotional Use Copyright © 2026 Verrica Pharmaceuticals. All rights reserved. Not For Promotional Use 1) Guenthner S, McFalda W, Kwong P, Eads K, McCafferty M, Rieger J, Glover DK, Willson C, Burnett P, Olivadoti M. COVE-1: A Phase 2, Open-Label Study to Evaluate Efficacy and Safety and the Optimal Regimen of VP-102, a Proprietary Drug-Device Product Containing Topical Cantharidin (0.7% w/v) Under Occlusion for the Treatment of Common Warts. Dermatol Ther (Heidelb). 2021 Oct;11(5):1623-1634. 2) July 1, 2025 Verrica Press Release; Verrica’s portion to be repaid out of future royalties and milestones. Global Phase 3 Program in Common Warts – The Expansion Opportunity • Verrica’s Global Phase 3 Program studying YCANTH for Common Warts leverages clinically meaningful activity on primary endpoint of complete clearance in Phase 2 COVE-1 study1 • Program gained alignment with FDA and PMDA on design of global Phase 3 program with Japanese development partner Torii Pharmaceutical • Two ongoing Phase 3 trials; First Phase 3 trial (COVE-2) fully enrolled with interim analysis recommending no additional patients needed (topline data expected in Q1 2027) and second Phase 3 trial (COVE-3) over 50% enrolled (topline data expected by mid-2027) • Torii to split program costs 50/50 with Verrica, but provide the first $40 million of out-of-pocket costs for the global study, representing approximately 90% of the current clinical budget(2) • Verrica maintains ownership of global rights to YCANTH for all indications in all territories outside of Japan and Israel 14

Page 15

Not For Promotional Use Copyright © 2026 Verrica Pharmaceuticals. All rights reserved. Not For Promotional Use 151) Guenthner 2019 Fall Clinical Dermatology Symposium Primary Efficacy Endpoint and Adverse Events in Phase 2 COVE-1 Study (Incidence ≥ 5%)1 Cohort 1 N=21 (to Day 84) Cohort 2 N=34 (to Day 147) Incidence: N (%) Application Site Vesicles * 20 (95.2) 27 (79.4) Application Site Pain * 15 (71.4) 26 (76.5) Application Site Erythema * 13 (61.9) 19 (55.9) Application Site Pruritus * 9 (42.9) 16 (47.1) Application Site Scab * 8 (38.1) 20 (58.8) Application Site Dryness * 6 (28.6) 13 (38.2) Application Site Edema * 4 (19.0) 6 (17.6) Application Site Discoloration * 1 (4.8) 8 (23.5) Application Site Exfoliation * 0 4 (11.8) Application Site Erosion * 0 3 (8.8) Papilloma Viral Infection ** 0 3 (8.8) * Local skin reactions were expected due to the pharmacodynamic action of cantharidin. ** Warts reported with verbatim term of ‘ring wart’ and coded to MeDRA. Of the 18 Cohort 2 subjects that showed complete clearance of lesions on Day 84, 14 subjects (78%) remained clear on Day 147

Page 16

Page 17

Not For Promotional Use Copyright © 2026 Verrica Pharmaceuticals. All rights reserved. Not For Promotional Use 17 Verrica believes VP-315 is Well-Positioned for Development Success Key Attributes Supportive Findings Phase 2 Efficacy Signal 97% ORR, robust complete histologic clearance and overall tumor burden reduction Safety / Tolerability Zero treatment-related SAEs across 93 lesions in Phase 2 trial FDA Regulatory Alignment EOP2 meeting completed; agreed Phase 3 Program design Phase 3 Trial Design 14-week primary endpoint, n=100 for each trial Mechanism Differentiation Novel localized treatment with dual mechanism MOA (direct necrosis and immune engagement) Potential Abscopal Effect Consistent with pre-clinical data and suggests potential for long-term disease modification Intellectual Property Runway Protection to 2032–2045 Rationale for Potential Phase 3 Success Phase 2 profile & FDA alignment on placebo-controlled endpoint and low BCC spontaneous resolution rate

Page 18

Not For Promotional Use Copyright © 2026 Verrica Pharmaceuticals. All rights reserved. Nearly 80% of patients surveyed would choose VP-315 over surgery, even when surgery is physician-recommended Patient Preference for Surgery vs. VP-315 73% 27% 0% 10% 20% 30% 40% 50% 60% 70% 80% VP-315 Surgery Respondents Source: Blacklight Partners survey with N=350 patients (commissioned by Verrica), April 2026 If offered access to an injection [of VP-315] prior to recommended surgery, what is your likelihood to choose to receive [VP-315] prior to any surgical procedure? 74% 26% 0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 VP-315 Surgery Respondents 80% 20% 0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 VP-315 Surgery Respondents BCC Experience Skin Cancer Experience (Not-BCC) No History of Skin Cancer 18

Page 19

Not For Promotional Use Copyright © 2026 Verrica Pharmaceuticals. All rights reserved. Not For Promotional Use 19 CD8+ T-cells infiltrate the tumor bed following VP-315 treatment Pre-treatmentPost-Treatment 0 50 100 150 200Cells / mm2 ✱ Subject 280-0010 Post-treatmentPre-treatment Tumor Bed^ p < 0.05 Pre-treatmentPost-Treatment 0 100 200 300 400 500Cells / mm2 ✱✱✱✱ p < 0.0001 Non-Tumor Region ^Tumor Bed defined as the area of residual tumor and/or inflammation and scar.

Page 20

Not For Promotional Use Copyright © 2026 Verrica Pharmaceuticals. All rights reserved. Not For Promotional Use 20 Reduced Immunosuppression in the Peritumoral^ Region Post VP-315 Treatment Immunosuppressive T Helper Cells Immunosuppressive CD8+ T-Cells Pre-treatmentPost-Treatment 0 100 200 300Cells / mm2 ✱✱ Pre-treatmentPost-Treatment 0 50 100 150 Cells / mm2 ✱ p < 0.05 p < 0.01 ^Within 75 µm outside of tumor/scar margin Subject 180-0015 Post-treatmentPre-treatment Immunosuppressive T Helper Cells Immunosuppressive CD8+ T-Cells Immunosuppressive T Regulatory Cells Immunosuppressive T Regulatory Cells p < 0.0001

Page 21

Not For Promotional Use Copyright © 2026 Verrica Pharmaceuticals. All rights reserved. 21 1) On August 6, 2026, the Company announced the closing of a credit facility of up to $27.5 million with an entity controlled by Paul B. Manning, Verrica’s Chairman and largest shareholder. 2) Consists of ~2.4 million Series B warrants (expiring November 2029, exercise price $13.35 per share) and ~3 million Series C warrants (expiring November 2030, exercise price $6.315) Financial Snapshot $11.2M $15.3M (+130% yoy) Up to $27.5M 17.2M Shares Outstanding (as of June 30, 2026) Cash as of June 30, 2026 YCANTH Revenue FY 2025 Access to Non-Dilutive Growth Capital; $12.5M available currently (1) Capital structure also includes: • 4.1 million pre-funded warrants (exercise price $0.0001 per share) • 5.4 million other warrants(2) • 4.2 million shares reserved under Equity Plans (including options and restricted stock units outstanding and reserved for issuance)$9.4M YCANTH Revenue H1 2026

Page 22

Not For Promotional Use Copyright © 2026 Verrica Pharmaceuticals. All rights reserved. THE PIPELINE • Global Phase 3 Program in Common Warts (over 3X as many patients) has the potential to substantially increase the addressable market for YCANTH • Development partner Torii is providing the first $40M of program costs (~90% of the current budget) 1 • Topline data expected in Q1 2027 from first Phase 3 trial (COVE-2) and mid-2027 from second Phase 3 trial (COVE-3) • VP-315 has the potential to change the approach for treating non-metastatic skin cancer, starting with Basal Cell Carcinoma, the most common form • Phase 3-ready program supported by alignment with FDA from End of Phase 2 meeting for two placebo-controlled pivotal trials, with long- term follow-up as a post-approval commitment Summary YCANTH® • Only FDA approved HCP-administered product with proven safety and efficacy in treatment of molluscum in adult and pediatric patients 2 years of age or older • Achieving greater brand recognition and adoption by dermatologists and pediatricians 22 COMPELLING OPPORTUNITY • Unique small cap company with commercial product and multiple late-stage development candidates addressing large unmet medical needs in dermatologic indications • Global Phase 3 Program studying YCANTH for the treatment of Common Warts ongoing with readouts targeted for Q1 2027 and mid-2027 • If approved for common warts, commercialization would leverage existing infrastructure developed for molluscum market • Significant YoY growth, with 130% and 99% growth in YCANTH revenue and Dispensed Applicator Units, respectively, in 2025, with continued growth in 2026 year-to-date • Verrica owns global rights for YCANTH outside existing partnerships in Japan and Israel and all global rights for non-metastatic skin cancer indications for VP-315, providing potential for expansion through partnerships 1) Verrica’s portion to be repaid out of future royalties and milestones; total program costs shared 50/50 with Torii.

Slides